Voya Investment Management LLC Has $98.90 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Voya Investment Management LLC trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 30.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,335,938 shares of the medical research company's stock after selling 576,083 shares during the quarter. Voya Investment Management LLC owned 0.23% of Edwards Lifesciences worth $98,899,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in EW. Harbor Capital Advisors Inc. boosted its stake in Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after purchasing an additional 273 shares during the period. Nordea Investment Management AB boosted its position in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after acquiring an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its stake in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after acquiring an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC bought a new position in Edwards Lifesciences during the fourth quarter worth $3,702,000. Finally, Avanza Fonder AB acquired a new position in Edwards Lifesciences during the 4th quarter valued at $4,845,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW traded down $1.11 during mid-day trading on Wednesday, hitting $75.17. 1,224,075 shares of the company traded hands, compared to its average volume of 4,979,688. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.19 billion, a price-to-earnings ratio of 10.78, a PEG ratio of 4.82 and a beta of 1.15. The business has a 50-day moving average of $70.99 and a 200 day moving average of $71.20. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.66 EPS. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the transaction, the vice president now owns 47,206 shares of the company's stock, valued at $3,295,450.86. This trade represents a 16.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,853 shares of company stock worth $5,163,062. Company insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $73.00 to $80.00 in a research report on Thursday, April 24th. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $79.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.